High level results on datopotamab raise safety and efficacy concerns, putting billion-dollar sales forecasts at risk.
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts.
The company’s stock surges 236% on first data with its new EGFR project, so where’s the catch?
After a hiatus Nkarta comes back with a new lymphodepletion regimen to boost its lead Car-NK therapy.
But Cologuard 2.0 has some punchy sales expectations to live up to.